Know what it is.
Know where it comes from.
Know what remains uncertain.
Know what it is. Know where it comes from. Know what remains uncertain.
FLOe Origin includes established procedures, off-label uses, compounded therapies, and emerging or investigational approaches. Many are **not FDA-approved for the specific musculoskeletal, aesthetic, hair, recovery, or whole-body purpose for which they may be considered.**
Before care is selected, we explain the exact treatment, source, proposed use, regulatory status, evidence, risks, uncertainties, alternatives, cost, and follow-up—including the option to choose no procedure.
Begin With Your GoalTreatments may overlap.
The reason for considering them should not.
Treatments may overlap. The reason for considering them should not.
Rather than repeating the same products three times, this page organizes options by what they are and where they come from. Each card carries one or more of the context tags:
Joints, tendons, ligaments, muscle, fascia, and movement
Skin, scalp, hair, scars, and subcutaneous tissue
Selected whole-person or systemic approaches
The tag identifies where a treatment may enter a clinical conversation. It does not establish FDA approval, effectiveness, eligibility, or availability.
Regulatory status and evidence are two different questions.
Regulatory status and evidence are two different questions.
FDA-approved or FDA-cleared
Applies only to a specific product or device and its labeled use. Device clearance does not automatically approve the treatment performed with it.
Off-label
Means an approved drug or cleared device is used outside its labeling. The proposed use itself has not been approved by FDA.
Compounded
Means a medication is prepared for a clinical need under applicable requirements. Compounded drugs are not FDA-approved and are not reviewed by FDA before marketing for safety, effectiveness, or quality.
Investigational or experimental
Describes a treatment or use with substantial uncertainty. The term does not create authorization. When an IND, IRB review, or another regulatory pathway is required, outcomes tracking alone cannot replace it.
Every treatment card should show:
**CONTEXT • REGULATORY STATUS • EVIDENCE STATUS**
Autologous options
Autologous options
Autologous means the material comes from you. It does not by itself establish FDA approval, effectiveness, low risk, or exemption from regulation.
PRP and PRF
Platelet-rich plasma and platelet-rich fibrin are prepared from your blood. Their composition varies with the collection system and protocol. They may be considered locally for selected musculoskeletal, skin, scalp, hair, or scar goals.
A2M-containing plasma preparations
Alpha-2-macroglobulin is a naturally occurring plasma protein. A2M-oriented treatments use a blood-processing method to produce a plasma preparation containing A2M and other components.
Bone marrow aspirate and concentrate — BMA/BMAC
Bone marrow is collected from your body and may be used as aspirate or processed into a concentrate containing a variable mixture of cells, platelets, plasma proteins, and signaling molecules.
Adipose-derived preparations
Adipose-derived treatment can mean intact structural fat, mechanically processed tissue, microfragmented adipose, or more extensively processed cellular products. These are not interchangeable.
Autologous platelet concentrate infusion — TruDose
TruDose uses a patient's blood to prepare an autologous platelet concentrate that is returned intravenously under a proprietary protocol.
A procedure is defined by the exact device, substance, route, and goal.
A procedure is defined by the exact device, substance, route, and goal.
Dextrose prolotherapy
A targeted injection procedure that commonly uses hypertonic dextrose, sometimes with anesthetic or other components, in or around selected musculoskeletal structures.
Ozone and prolozone
Local ozone uses a defined oxygen-ozone gas mixture. Prolozone is a nonstandardized combination that may include anesthetic, dextrose or other injectates, followed by an oxygen-ozone mixture.
Microneedling
A controlled mechanical procedure that creates small channels in the skin and may be considered for selected texture, wrinkle, or scar goals.
RF microneedling — Morpheus8
Microneedling combined with radiofrequency energy for selected dermatologic procedures involving tissue coagulation or contraction.
Scar & Tissue Remodeling
A personalized approach to the visible scar and the tissue around and beneath it—including texture, color, tethering, stiffness, subcutaneous mobility, and fascial glide.
The plan may use one or more available procedural or autologous options. Each component keeps its own regulatory status, evidence, risks, and consent; "Scar & Tissue Remodeling" is a clinical pathway, not one FDA-approved treatment.
The exact molecule matters.
The exact molecule matters.
"Peptide" is a chemical description—not an approval status or clinical outcome. Some peptide drugs are FDA-approved for specific indications. That status does not extend to a different molecule, compounded formulation, dose, route, combination, or regenerative purpose.
Compounded peptides are not FDA-approved. Before any Peptide Therapy is considered, FLOe reviews the exact molecule and form, route, pharmacy or manufacturer, proposed use, evidence, safety uncertainties, alternatives, planned duration, reassessment point, and stop criteria.
**BPC-157**
Not FDA-approved; experimental, with limited human safety and effectiveness data.
**TB-500 / thymosin beta-4 fragment**
Not FDA-approved; experimental, with insufficient human clinical evidence.
**Injectable GHK-Cu**
Not FDA-approved for skin, hair, wound-healing, or systemic regenerative purposes; human safety and clinical evidence are limited.
Peptide Therapy is targeted support where medically appropriate—not an automatic, indefinite protocol or a requirement of care.
Included for transparency—not presented as a routine treatment menu.
Included for transparency—not presented as a routine treatment menu.
Products marketed as placental, amniotic, umbilical-cord, Wharton's-jelly, or exosome-based can differ substantially in source, processing, composition, route, intended use, and regulatory status.
These terms are not interchangeable, and not every product in this group should be called an "allograft." Their possible relevance may span MSK, Aesthetics, or Embodiment, but that overlap does not establish approval or lawful availability.
Placental tissue products
Some minimally manipulated placental membrane products may qualify for regulation solely under section 361 when used for an appropriate homologous function, such as serving as a covering or barrier. Injection or use for orthopedic repair, aesthetic rejuvenation, hair growth, or systemic treatment is a different use and may require approval as a drug or biological product or administration under an effective IND.
Purified amniotic-fluid products
Amniotic fluid is generally not treated by FDA as an HCT/P because it is a secreted body fluid. A purified amniotic-fluid product intended to treat disease or alter tissue is generally regulated as a drug and biological product and requires appropriate premarket approval or investigational authorization.
Wharton's-jelly and umbilical-cord-derived products
These may contain processed extracellular matrix, cells, fluid, or other components derived from umbilical-cord tissue. FDA has stated that such products are not approved for orthopedic conditions, and uses aimed at tissue repair, aesthetic change, or systemic effect commonly raise minimal-manipulation and nonhomologous-use concerns.
Exosomes and extracellular-vesicle products
Exosome products differ in cell source, purification, characterization, dose, and storage. FDA states that there are currently **no FDA-approved exosome products.** Products intended to treat disease or alter tissue function generally require approval as drugs or biological products or use under an effective IND.
Treatment is one part of the recovery environment.
Treatment is one part of the recovery environment.
Tissue does not respond in isolation. Joints, tendons, fascia, skin, scalp, scars, and subcutaneous tissue exist within a larger environment of extracellular matrix, circulation, mechanical loading, metabolism, sleep, nutrition, stress physiology, and time.
Before, during, and after a procedure, FLOe may address breath, movement, load, nourishment, hydration, sleep, circulation, and recovery behaviors. These steps may become the entire plan, prepare the ground for a procedure, or help integrate care afterward. They do not guarantee healing or change a treatment's FDA status.
The destination comes first.
The destination comes first.
We begin with what you want to regain, then assess the tissue, the wider physiologic context, prior care, reasonable alternatives, and your tolerance for risk, cost, time, and uncertainty.
Before treatment, we review:
The aim is the least complicated meaningful next step—not the newest or most expensive option.
The response becomes part
of the map.
The response becomes part of the map.
Every Origin plan begins with a baseline and the outcomes that matter to you. Depending on the goal, FLOe may follow symptoms, function, movement, performance, appearance, physiologic measures, lived experience, durability, additional treatment, and adverse events.
Your response guides the next decision: continue, modify, pause, stop, or choose another path.
With separate consent, eligible patients may also participate in a structured longitudinal outcomes registry. Participation is voluntary, is not required to receive care, and does not guarantee benefit. Registry findings may improve follow-up, but they do not by themselves establish causation, safety, effectiveness, or FDA approval—and they do not authorize an investigational product.
Transparency does not remove uncertainty.
It makes uncertainty visible enough to support a sound decision.
Transparency does not remove uncertainty. It makes uncertainty visible enough to support a sound decision.
Our responsibility is not to convince you to receive the most advanced treatment. It is to help you understand the options, prepare the ground, and choose the simplest meaningful next step toward the possibility you want back.
This page is for general education and does not replace an individualized medical evaluation or treatment-specific informed consent. Treatment availability, evidence, and regulatory status may change. No result is guaranteed.